T-type Ca2+ channel enhancer SAK3 administration improves the BPSD-like behaviors in AppNL−G-F/NL−G-F knock-in mice

Tomohide Degawa, Ichiro Kawahata, Hisanao Izumi, Yasuharu Shinoda, Kohji Fukunaga

Research output: Contribution to journalArticlepeer-review


Alzheimer's disease (AD) accounts for the majority of dementia among the elderly. In addition to cognitive impairment, behavioral and psychological symptoms (BPSD) such as depression tendency and increased aggression impose a great burden on the patient. However, there is still no rational therapeutic drug for BPSD. Recently, we developed a novel AD therapeutic candidate, SAK3, and demonstrated that it improved cognitive dysfunction in AppNL-G-F/NL-G-F knock-in (NL-G-F) mice. In this study, we investigated whether acute SAK3 administration improved BPSD in addition to cognitive improvement. Acute SAK3 administration improved BPSD, including anxiolytic and depressive-like behaviors, and ameliorated aggressive behaviors. Furthermore, continuous SAK3 administration improved anxiolytic and depressive-like behaviors. Intriguingly, the anti-anxiolytic and cognitive improvement lasted two weeks after the withdrawal of SAK3, whereas the anti-depressive action did not. Taken together, SAK3 had comprehensive beneficial effects on BPSD behavior.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Pharmacological Sciences
Issue number1
Publication statusPublished - 2021 May


  • Alzheimer's disease
  • BPSD
  • SAK3
  • T-type Ca channel

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'T-type Ca<sup>2+</sup> channel enhancer SAK3 administration improves the BPSD-like behaviors in App<sup>NL−G-F/NL−G-F</sup> knock-in mice'. Together they form a unique fingerprint.

Cite this